复宏汉霖(02696.HK) 公布,近日,重组抗VEGF人源化单克隆抗体注射液HLX04-O在一项于湿性年龄相关性黄斑变性中国患者中开展的3期临床研究达到主要研究终点。结果显示,HLX04-O组第48周最佳矫正视力较基线改善的平均字母数变化结果非劣于雷珠单抗组。HLX04-O是在公司自主研发的汉贝泰的基础上开发的新的眼科制剂产品。2020年10月,公司将汉贝泰于全球范围眼科治疗用途和/或疗法的独家...
Source Link复宏汉霖(02696.HK) 公布,近日,重组抗VEGF人源化单克隆抗体注射液HLX04-O在一项于湿性年龄相关性黄斑变性中国患者中开展的3期临床研究达到主要研究终点。结果显示,HLX04-O组第48周最佳矫正视力较基线改善的平均字母数变化结果非劣于雷珠单抗组。HLX04-O是在公司自主研发的汉贝泰的基础上开发的新的眼科制剂产品。2020年10月,公司将汉贝泰于全球范围眼科治疗用途和/或疗法的独家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.